{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:58:04Z","timestamp":1765727884169,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"name":"LLC"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.jval.2020.06.007","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T18:17:50Z","timestamp":1600453070000},"page":"1286-1291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial"],"prefix":"10.1016","volume":"23","author":[{"given":"M. Elaine","family":"Husni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric K.H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth C.","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilianne","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim Hung","family":"Lo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane D.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenglong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.jval.2020.06.007_bib1","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2020.06.007_bib2","series-title":"Primer on the Rheumatic Diseases","article-title":"Psoriatic arthritis","author":"Boumpas","year":"2001"},{"key":"10.1016\/j.jval.2020.06.007_bib3","first-page":"511","article-title":"Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis","volume":"53","author":"Leonard","year":"1978","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jval.2020.06.007_bib4","first-page":"1247","article-title":"The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991","volume":"27","author":"Shbeeb","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jval.2020.06.007_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40257-013-0032-x","article-title":"Burden of disease: psoriasis and psoriatic arthritis","volume":"14","author":"Boehncke","year":"2013","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jval.2020.06.007_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jval.2020.06.007_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) Survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jval.2020.06.007_bib8","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jval.2020.06.007_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jval.2020.06.007_bib10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jval.2020.06.007_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"year":"1994","series-title":"Interpretation: Norm-Based. SF-36 Physical and Mental Health Summary Scales: A User's Manual","author":"Ware","key":"10.1016\/j.jval.2020.06.007_bib12"},{"key":"10.1016\/j.jval.2020.06.007_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00019053-200422001-00004","article-title":"Patient-reported outcomes and their role in the assessment of rheumatoid arthritis","volume":"22","author":"Lubeck","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.06.007_bib14","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.jval.2020.06.007_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2020.06.007_bib16","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.jval.2020.06.007_bib17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jval.2020.06.007_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jval.2020.06.007_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-1-20","article-title":"The Stanford Health Assessment Questionnaire: dimensions and practical applications","volume":"1","author":"Bruce","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2020.06.007_bib20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2020.06.007_bib21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do dermatology life quality index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jval.2020.06.007_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/kew009","article-title":"Distress, misperceptions, poor coping and suicidal ideation in psoriatic arthritis: a qualitative study","volume":"55","author":"Chisholm","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jval.2020.06.007_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/01.NPR.0000461950.23292.18","article-title":"Management of patients with psoriatic arthritis","volume":"40","author":"Dewing","year":"2015","journal-title":"Nurse Pract"},{"key":"10.1016\/j.jval.2020.06.007_bib24","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1136\/annrheumdis-2013-204867","article-title":"Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry","volume":"74","author":"Sorensen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jval.2020.06.007_bib25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdv.13306","article-title":"Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience","volume":"30","author":"Betteridge","year":"2015","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jval.2020.06.007_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1023\/A:1012552211996","article-title":"Do SF-36 summary component scores accurately summarize subscale scores?","volume":"10","author":"Taft","year":"2001","journal-title":"Qual Life Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520322038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520322038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:20:25Z","timestamp":1761096025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520322038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1098301520322038"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.06.007","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}